5820-27-9

Basic information

• Product Name: 1-bromo-4-[(2-methylprop-2-en-1-yl)oxy]benzene
• CAS NO: 5820-27-9
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.0977
• Mol File: 5820-27-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 270.5°C at 760 mmHg
• Flash Point: 116.9°C
• Density: 1.304g/cm³
• Vapor Pressure: 0.0113mmHg at 25°C
• Refractive Index: 1.533
• CAS DataBase Reference: 1-bromo-4-[(2-methylprop-2-en-1-yl)oxy]benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-4-[(2-methylprop-2-en-1-yl)oxy]benzene(5820-27-9)
• EPA Substance Registry System: 1-bromo-4-[(2-methylprop-2-en-1-yl)oxy]benzene(5820-27-9)

Safety Data

• Hazardous Substances Data: 5820-27-9(Hazardous Substances Data)

Usage

Molecular weight

227.09 g/mol
The mass of one mole of 1-bromo-4-[(2-methylprop-2-en-1-yl)oxy]benzene is 227.09 grams.

Physical state

Colorless liquid
The compound exists in a liquid state and is colorless in appearance.

Odor

Characteristic sweet odor
The compound has a distinct, sweet smell that can be detected by the human nose.

Uses

Organic synthesis, intermediate in pharmaceuticals and agrochemicals
The compound is utilized in the synthesis of various organic compounds and serves as a precursor in the production of pharmaceuticals and agrochemicals.

Environmental impact

Potential environmental pollutant
The compound has been identified as a potential pollutant, which means it can have negative effects on the environment if not handled properly.

Health hazards

Irritant to eyes, skin, and respiratory system
Exposure to the compound can cause irritation to the eyes, skin, and respiratory system, emphasizing the need for proper handling and safety precautions.

Safety

Handle with care
Due to its potential environmental and health hazards, the compound should be handled with care and appropriate safety measures should be taken during its use and storage.

Upstream product

• 106-41-2 4-bromo-phenol 
• 1458-98-6 2-methyl-3-bromo-1-propene 
• 589-87-7 1,4-bromoiodobenzene 
• 513-42-8 3-hydroxy-2-methyl-1-propene 
• 563-47-3 3-Chloro-2-methylpropene 

Downstream Products

• 1165738-86-2 4-bromo-2-(2’-methylallyl)phenol 
• 38002-92-5 2,3-dihydro-2,2-dimethylbenzofuran-5-carboxaldehyde 
• 5337-94-0 5-Bromo-2,2-dimethyl-2,3-dihydrobenzo[b]furan 
• 5842-41-1 3-(4-bromo-phenoxy)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester 
• 5842-42-2 trans-3-<4-Brom-phenoxy>-2,2-dimethyl-cyclopropan-1-carbonsaeure 
• 5820-34-8 (4-bromo-phenyl)-(2-methyl-propenyl)-ether 
• 66129-05-3 C₁₀H₁₁BrCl₂OS 

Relevant articles and documents

Enantioselective Synthesis of 3-Fluorochromanes via Iodine(I)/Iodine(III) Catalysis

The chromane nucleus is common to a plenum of bioactive small molecules where it is frequently oxidized at position 3. Motivated by the importance of this position in conferring efficacy, and the prominence of bioisosterism in drug discovery, an iodine(I)/iodine(III) catalysis strategy to access enantioenriched 3-fluorochromanes is disclosed (up to 7:93 e.r.). In situ generation of ArIF2 enables the direct fluorocyclization of allyl phenyl ethers to generate novel scaffolds that manifest the stereoelectronic gauche effect. Mechanistic interrogation using deuterated probes confirms a stereospecific process consistent with a type IIinv pathway.

Catalytic Isohypsic-Redox Sequences for the Rapid Generation of Csp3-Containing Heterocycles

Cross-coupling reactions catalyzed by transition metals are among the most influential in modern synthetic chemistry. The vast majority of transition-metal-catalyzed cross-couplings rely on a catalytic cycle involving alternating oxidation and reduction o

LXR MODULATORS

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXR), compositions comprising any of such novel compounds, methods of using these compounds or compositions as medicaments for prevention or treatment of diseases or disorders related to liver X receptor (LXR), as well as methods of preparing these LXR modulators and using them in the manufacture of medicaments.